Meeting
2023 ASCO Annual Meeting
Adjuvant nab-paclitaxel plus S-1 versus capecitabine plus oxaliplatin for patients with stage III gastric adenocarcinoma after D2 dissection: A multicenter, open-label, randomized phase 3 study.
Authors
Yu Pengfei
Zhejiang Cancer Hospital (University of Chinese Academy of Sciences Cancer Hospital), Hangzhou, China
Yu Pengfei , Yian Du , Zhiyuan Xu , Litao Yang , Jieer Ying , Ping Chen , Yunhai Wei , Yingjie Wu , Xiaojing Zhang , Zhilong Yan , Zhiheng Chen , Hongtao Xu , Yong Li , Zhichao Zheng , Nong Xu , Xiangdong Cheng
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer - Local-Regional Disease
Clinical Trial Registration Number
NCT04135781
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 4054)
DOI
10.1200/JCO.2023.41.16_suppl.4054
Abstract #
4054
Poster Bd #
375
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Adjuvant nab-paclitaxel plus S-1 versus oxaliplatin plus capecitabine after curative D2 gastrectomy in patients with stage III gastric adenocarcinoma: a phase 3 open-label, randomized controlled trial
First Author: Yu Pengfei
Poster
2022 ASCO Annual Meeting
A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
First Author: Yu Pengfei
Poster
2023 ASCO Annual Meeting
STAR-221: A randomized, open-label, multicenter, phase 3 trial of domvanalimab, zimberelimab, and chemotherapy versus nivolumab and chemotherapy in previously untreated, locally advanced, unresectable or metastatic gastric, gastroesophageal junction, and esophageal adenocarcinoma.
First Author: Samuel J Klempner
Poster
2023 ASCO Annual Meeting
Neoadjuvant short-course radiotherapy followed by chemotherapy plus camrelizumab versus long-course chemoradiotherapy followed by chemotherapy for patients with locally advanced rectal cancer: A randomized, multicenter, open-label phase 3 trial (Union).
First Author: Zhenyu Lin